<DOC>
	<DOCNO>NCT02529579</DOCNO>
	<brief_summary>The aim study evaluate safety efficacy iAPA-DC/CTL combined gemcitabine therapy advance pancreatic cancer .</brief_summary>
	<brief_title>Safety Efficacy Evaluation iAPA-DC/CTL Combined Gemcitabine Therapy Advanced Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Pancreatic Ductal</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>1 . Advanced Pancreatic cancer patient histological pathology confirmation 2 . Both gender , age 1870 yearold 3 . Bone marrow function well 4 . Renal function normal 5 . Liver function normal 6. patient voluntary , willing sign inform consent 7. expect lifetime least 3 month 1 . With acute inflammation 2 . Accompanied primary malignant tumor pancreas 3. autoimmune disease 4. use corticosteroid suppress immune hormone treatment 5. transplant operation vital organ 6. active hepatitis 7 . HIV positive 8. dysfunction blood coagulation 9. serious disease circulatory respiratory system 10. pregnancy breastfeed woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>adoptive Cellular Immunotherapy</keyword>
	<keyword>patient safety</keyword>
	<keyword>therapeutic effect</keyword>
</DOC>